The therapeutic monitoring of antimicrobial agents

British Journal of Clinical Pharmacology

Volumn 47, Issue 1, 1999, Pages 23-30

  Begg, Evan J ^a   Barclay, Murray L ^a   Kirkpatrick, Carl J M ^a  

^a CHRISTCHURCH HOSPITAL   (New Zealand)

Author keywords

Antimicrobial agents; Therapeutic drug monitoring

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; FLUCYTOSINE; ITRACONAZOLE; TEICOPLANIN; VANCOMYCIN;

ARTICLE; COST EFFECTIVENESS ANALYSIS; DRUG MONITORING; PRIORITY JOURNAL;

AMINOGLYCOSIDES; ANTI-INFECTIVE AGENTS; ANTIFUNGAL AGENTS; DRUG MONITORING; FLUCYTOSINE; HUMANS; ITRACONAZOLE; TEICOPLANIN; VANCOMYCIN;

EID: 0032898587     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.1999.00850.x     Document Type: Article

References (64)

1. 1 Begg EJ, Barclay ML. Aminoglycosides - 50 years on. Br J Clin Pharmacol 1995; 39: 597-603.
2. 2 Benet LZ, Williams RL. Design and optimisation of dosage regimens. In The Pharmacological Basis of Therapeutics, Eight Edition, eds Gilman AG, Rall TW, Nies AS, Taylor P, New York: Pergamon Press, 1990: 1650-1735.
3. 3 Zaske DE, Cipolle RJ, Solem LD, Strate RG. Rapid individualization of gentamicin dosage regimens in 66 burn patients. Burns 1981; 7: 215-220.
4. 4 Hoey LL, Tschida SJ, Rotschafer JC, Guay DRP, Vance-Bryan K. Wide variation in single daily dose aminoglycoside pharmacokinetics in patients with burn injuries. J Burn Care Rehabil 1997; 18: 116-124.
5. 5 Barclay ML, Begg EJ. Aminoglycoside toxicity and relation to dose regimen. Adverse Drug React Toxicol Rev 1994; 13: 207-234.
6. 6 Noone P, Parsons TMC, Pattison JR, Slack RCB, Garfield-Davies D, Hughes K. Experience in monitoring gentamicin therapy during treatment of serious gram-negative sepsis. Br Med J 1974; 1: 477-481.
7. 7 Moore RD, Smith CR, Lietman PS. The association of aminoglycoside plasma levels with mortality in patients with gram-negative bacteremia. J Infect Dis 1984; 149: 443-448.
8. 8 Moore RD, Smith CR, Lietman PS. Association of aminoglycoside plasma levels with therapeutic outcome in gram-negative pneumonia. Am J Med 1984; 77: 657-662.
9. 9 Prins JM, Buller HR, Kuijper EJ, Tange RA, Speelman P. Once versus thrice daily gentamicin in patients with serious infections, Lancet 1993; 341: 335-339.
10. 10 Konrad F, Wagner R, Neumeister B, Rommel H, Georgieff M. Studies on drug monitoring in thrice and once daily treatment with aminoglycosides. Intensive Care Med 1993; 19: 215-220.
11. 11 Ter Draak EW, De Vries PJ, Bouter KP, et al. Once-daily dosing regimen for aminoglycoside plus B-lactam combination therapy of serious bacterial infections: Comparative trial with netilmicin plus ceftriaxone. Am J Med 1990; 89: 58-66.
12. 12 Begg EJ, Barclay ML, Duffull SB. A suggested approach to once-daily aminoglycoside dosing. Br J Clin Pharmacol 1995; 39: 605-609.
13. 13 Morike K, Schwab M, Klotz U. Use of aminoglycosides in elderly patients - pharmacokinetic and clinical considerations. Drugs & Aging 1997; 10: 259-277.
14. 14 Sawchuk RJ, Zaske DE, Cipolle RJ, Wargin WA, Strate RG. Kinetic model for gentamicin dosing with the use of individual patient parameters. Clin Pharmacol Ther 1977; 21: 362-369.
15. 15 Begg EJ, Atkinson HC, Jeffery GM, Taylor NW. Individualised aminoglycoside dosage based on pharmacokinetic analysis is superior to dosage based on physician intuition at achieving target plasma drug concentrations. Br J Clin Pharmacol 1989; 28: 137-141.
16. 16 Hickling K, Begg E, Moore ML. A prospective randomised trial comparing individualised pharmacokinetic dosage prediction for aminoglycosides with prediction based on estimated creatinine clearance in critically ill patients. Intensive Care Med 1989; 15: 233-237.
17. 17 Burton ME, Brater DC, Chen PS, Day RB, Huber PJ, Vasko MR1. A Bayesian feedback method of aminoglycoside dosing. Clin Pharmacol Ther 1985; 37: 349-355.
18. 18 MacGowan A, Reeves D. Serum aminoglycoside concentrations: the case for routine monitoring. J Antimicrob Agents 1994; 34: 829-837.
19. 19 Nicolau DP, Freeman CD, Belliveau PP, Nightingale CH, Ross JW, Qintiliani R. Experience with a once-daily aminoglycoside program administered to 2184 adult patients. Antimicrob Agents Chemother 1995; 39: 650-655.
20. 20 El Bakri F, Pallett A, Smith AG, Duncombe AS. Ototoxicity induced by once-daily gentamicin. Lancet 1998, 351: 1407-1408.
21. 21 Duffull SB, Kirkpatrick CMJ, Begg EJ. Comparison of two Bayesian approaches to dose-individualisation for once daily dosing regimens. Br J Clin Pharmacol 1997; 43: 125-135.
22. 22 Hickling KG, Begg EJ, Perry RE, Atkinson HC, Sharman JR. Serum aminoglycoside clearance is predicted as poorly by renal aminoglycoside clearance as by creatinine clearance in critically ill patients. Crit Care Med 1991; 19: 1041-1047.
23. 23 Trissel LA (ed). Handbook on Injectable Drugs. Sixth Edition, Bethesda, USA: Am Soc Hospital Pharmacists, 1990: 358-361.
24. 24 Destache CJ, Meyer SK, Rowley KM. Does accepting pharmacokinetic recommendations impact hospitalization? A cost-benefit analysis. Ther Drug Monitor 1990; 12: 427-433.
25. 25 Crist KD, Nahata MC, Ety J. Postive impact of a therapeutic drug-monitoring program on total aminoglycoside dose and cost of hospitalization. Ther Drug Monitor 1987; 9: 306-310.
26. 26 Nicolau DP, Wu AHB, Finocchiaro S, et al. Once-daily aminoglycoside dosing: Impact on requests and costs of therapeutic drug monitoring. Ther Drug Monitor 1996; 18: 263-266.
27. 27 Edwards DJ, Pancorbo S. Routine monitoring of serum vancomycin concentrations: waiting for proof of its value. Clin Pharm 1987; 6: 652-654.
28. 28 Freeman CD, Quintiliani R, Nightingale CH. Vancomycin therapeutic drug monitoring: is it necessary? Ann Pharmacother 1993; 27: 594-598.
29. 29 Saunders NJ. Why monitor peak vancomycin concentrations? Lancet 1994; 344: 1748-1750.
30. 30 Duffull SB, Begg EJ. Vancomycin toxicity. What is the evidence for dose dependency? Adverse Drug React Toxicol Rev 1994; 13: 103-114.
31. 31 Dufull SB, Chambers ST, Begg EJ. How vancomycin is used in clinical practice - a survey. Aust NZ J Med 1993; 23: 662-666.
32. 32 Geraci JE, Heilman FR, Nichols DR, Wellman WE. Antibiotic therapy of bacterial endocarditis. VII. Vancomycin for acute micrococcal endocarditis. Staff Meetings of the Mayo Clinic 1958; 33: 172-181.
33. 33 Rybak MJ, Albrecht LM, Boike SC, Chandresekar PH. Nephrotoxicity of vancomycin, alone and with an aminoglycoside. J Antimicrob Chemother 1990; 25: 679-687.
34. 34 Cimino MA, Rotstein C, Slaughter RL, Emrich LJ. Relationship of serum antibiotic concentrations to nephrotoxicity in cancer patients receiving concurrent aminoglycoside and vancomycin therapy. Am J Med 1987; 83: 1091-1096.
35. 35 Garrelts JC, Godley PJ, Horton MW, Karboski JA. Accuracy of Bayesian, Sawchuk-Zaske, and nomogram dosing methods for vancomycin. Clin Pharm 1987; 6: 795-799.
36. 36 Healy DP, Sahai JV, Fuller SH, Polk RE. Vancomycin-induced histamine release and 'red man syndrome': Comparison of 1 and 2 hour infusions. Antimicrob Agents Chemother 1990; 34: 550-555.
37. 37 Lake KD, Peterson CD. A simplified dosing method for initiating vancomycin therapy. Pharmacotherapy 1985; 5: 340-344.
38. 38 Matzke GR, McGory RW, Halstenson CE, Keane WF. Pharmacokinetics of vancomycin in patients with various degrees of renal function. Antimicrob Agents Chemother 1984; 25: 433-437.
39. 39 Moellering RC Jr. Pharmacokinetics of vancomycin. J Antimicrob Chemother 1984; 14: 43-52.
40. 40 Ackerman BH, Olsen KM, Padilla CB. Errors in assuming a one-compartment model for vancomycin. Ther Drug Monit 1990; 12: 304-305.
41. 41 Burton ME, Gentle DL, Vasko MR. Evaluation of a Bayesian method for predicting vancomycin dosing. DICP 1989; 23: 294-299.
42. 42 Hurst AK, Yoshinaga MA, Mitani GH, Foo KA, Jelliffe RW, Harrison EC. Application of a Bayesian method to monitor and adjust vancomycin dosage regimens. Antimicrob Agents Chemother 1990; 34: 1165-1171.
43. 43 Pryka RD, Rodvold KA, Garrison M, Rotschafer JC. Individualizing vancomycin dosage regimens: one-versus two-compartment Bayesian models. Ther Drug Monit 1989; 11: 450-454.
44. 44 Hu MW, Anne L, Forni T, Gottwald K. Measurement of vancomycin in renally impaired. Analytical Abstracts 1991; 53: 1321-1322.
45. 45 White LO, Edwards R, Holt HA, Lovering AM, Finch RG, Reeves DS. The in-vitro degradation at 37° C of vancomycin in serum, CAPD fluid and phosphate-buffered saline. J Antimicrob Chemother 1988; 22: 739-745.
46. 46 Morse GD, Nairn KD, Bertino SJ, Walshe JJ. Overestimation of vancomycin concentrations utilising fluoescence polarising immunoassay in patients on peritoneal dialysis. Ther Drug Monitor 1987; 9: 212-215.
47. 47 Welty TE, Copa AK. Impact of vancomycin therapeutic drug monitoring on patient care. Ann Pharmacother 1994; 28: 1335-1399.
48. 48 Lake KD, Peterson CD. Evaluation of a method for individualising vancomycin therapy: experience in 205 patients. Pharmacotherapy 1988; 8: 284-286.
49. 49 Brogden RN, Peters DH. Teicoplanin. A reappraisal of its antimicrobial activity, pharmacokinetic properties and therapeutic efficacy. Drugs 1994; 47: 823-854.
50. 50 Wood MJ. The comparative efficacy and safety of teicoplanin and vancomycin. J Antimicrob Chemother 1996; 37: 209-222.
51. 51 Bourget P, Lesne-Hulin A, Sertin A, Maillot A, Alaya M, Martin C. Fluorescence polarization immunoassay: Does it always represent a reliable method to monitor treatment with teicoplanin? Comparison with data obtained by high-performance liquid chromatography. Int J Pharmaceut 1997; 146: 167-174.
52. 52 Reeves DS, MacGowan AP, Holt HA, Lovering AM, Warnock DW, White LO. Therapeutic monitoring of antimicrobials. J Antimicrob Chemother 1995; 35: 213-226.
53. 53 Steer JA, Papini RP, Wilson AP, et al. Pharmacokinetics of a single dose of teicoplanin in burn patients. J Antimicrob Chemother 1996; 37: 545-553.
54. 54 Sahai J, Healy DP, Shelton MJ, Miller JS, Ruberg SJ, Polk R. Comparison of a vancomycin and teicoplanin-induced histamine release and 'red man syndrome'. Antimicrob Agents Chemother 1990; 34: 765-769.
55. 55 Summers KK, Hardin TC, Gore SJ, Grayhill JR. Therapeutic drug monitoring of systemic antifungal therapy. J Antimicrob Chemother 1997; 40: 753-764.
56. 56 Lyman CA, Walsh TJ. Systemically administered antifungal agents. A review of their clinical pharmacology and therapeutical applications. Drugs 1992; 44 (1): 9-35.
57. 57 Kauffman CA, Frame PT. Bone marrow toxicity associated with 5-fluorocytosine therapy. Antimicrob Agents Chemother 1977; 11: 244-247.
58. 58 Stamm AM, Diasio RB, Dismukes WE, Shadomy S, Cloud GA, Bowles CA. Toxicity of amphotericin B plus flucytosine in 194 patients with cryptococcal meningitis. Am J Med 1987; 83: 236-242.
59. 59 Viviani MA. Flucytosine - what is its future? J Antimicrob Chemother 1995; 35: 241-244.
60. 60 Tucker RM, Denning DW, Hanson LH, et al. Interaction of azoles with rifampin, phenytoin and carbamazepine: in vitro and clinical observations. Clin Infect Dis 1992; 14: 165-174.
61. 61 Kintzel PE, Rollins CJ, Yee WJ, List AF. Low itraconazole serum concentrations following administration of itraconazole suspension to critically ill allogenic bone marrow transplant recipients. Ann Pharmacother 1995; 29: 140-143.
62. 62 Tricot G, Joosten G, Boogaetrs MA, Van de Pitte J, Cauwenbergh G. Ketoconazole vs itraconazole for antifungal prophylaxis in patients with severe granulocytopenia: preliminary results of two randomised studies. Reviews of Infectious Diseases 1987; 9 (Suppl. 1): 94-99.
63. 63 Van Custen J. The in vitro antifungal spectrum of itraconazole. Mycoses 1989; 32: 7-13.
64. 64 Poirier JM, Lebot M, Descamps P, Levy M, Cheymol G. Determination of itraconazole and its active metabolite in plasma by column liquid chromatography. Ther Drug Monit 1994; 16: 596-601.